If you're attending BIO Convention, be sure to stop by the Company Presentations at 3:15 pm today to watch our VP of Strategy & Solutions Management present on how analysis of real-world molecular data empowers the drug lifecycle #BIO2018 #BioInternationalConvention2018

Webinar Thurs 6/21 2pm Eastern: Join our panel of industry leaders and BioPharma Dive as they explore how molecular #biomarkers are driving #companiondiagnostics, the implications for expanding #molecularbiomarker profiles in the future, and much more. bit.ly/2K0wUw7

From STAT on the barriers to genomic testing: Of more than 160 oncologists surveyed about #precisionmedicine and genomic testing, "One-third of respondents said they wait 15 days or more to receive test results.": bit.ly/2tblLT6

Honored to be named among the “top of mind" #precisionmedicine vendors by KLAS Research. From Healthcare IT News bit.ly/2N6f7VC "Soon precision medicine may be considered the standard of care... a small # of precision med vendors have high mindshare among healthcare provider

From Genetic Engineering & Biotechnology News: Sequencing Circulating Tumor DNA Can Provide a More Complete Molecular Picture bit.ly/2O9yUEM

Article by N-of-One science & business leaders from Nature Biotechnology "Expert curation is currently the only approach that provides a consistent and accurate clinical interpretation that is backed by defendable and transparent reason and evidence": go.nature.com/2nfzHrN

If you’re attending #AMP2018 Corporate Workshop Day, be sure not to miss “Helping Pathologists Make the Right Calls in #PrecisionMedicine” at 4:00 pm in room 303AB

Head on over to room 303AB at #AMP2018 Corporate Workshop Day for a discussion of the complexities around making the right calls in #PrecisionMedicine

N-of-One’s Kelly Sullivan is presenting a poster discussing an analysis of ARID1A mutations and co-occurring gene variants in #cancer biopsies at #AMP2018

We are pleased to announce the acquisition of N-of-One to expand our clinical bioinformatics capabilities in molecular oncology decision support. Their Insights reporting tools and MarkerMine database will be integrated into our QCI portfolio. corporate.qiagen.com/newsroom/press…

.QIAGEN Acquires N-of-One to Add Molecular Decision Support genomeweb.com/business-news/…

As part of the Genetic Engineering & Biotechnology News Magazine relaunch, there is a great article covering the high stakes in #drugdevelopment for #precisionmedicine, featuring our Chief Scientific Officer, Dr. Sheryl Elkin: bit.ly/2SOPZG9

ICYMI: Our own CSO Sheryl Elkin on a panel this morning at #PMWC2019, led by Sean Scott of QIAGEN, discussing the current state of molecular test interpretation and reporting, and how real-world data can be leveraged in #precisionmedicine

Strategic advisor Chris Cournoyer in recent @ClinicalOMICs article on #BigData & #ClinicalGenomics: “There’s a big data normalization problem. Big data sits in silos across any hospital system.” Read more on how expanding datasets will affect the landscape bit.ly/2XV86MD

N-of-One's Dr. Kelly Sullivan explains “comprehensive #biomarker analysis is about narrowing & expanding the pool of eligible patients at the same time" re: combination biomarkers for drug development in #precisiononcology in recent Genetic Engineering & Biotechnology News piece: bit.ly/2YatL3B

QIAGEN and N-of-One proudly present a joint webinar about finding the right precision medicine solution for your clinical #NGS testing lab today. Register now: fal.cn/Avs4

We’re excited for our first year with N-of-One at #ASCO19! Stop by QIAGEN booth 24103 to learn about N-of-One’s molecular decision support services #PrecisionOncology fal.cn/AcbV

Register now for GEN’s webinar July 16 at 11 am ET for a panel of diverse experts led by N-of-One (A QIAGEN Company) Solutions Manager Kelly Sullivan discussing assessing the validity of #biomarkers to inform #drugdevelopment and potential combo therapies: bit.ly/2YejILb

If you’re attending #AACR18, be sure to stop by booth 1138 to see our analysis of ARID1A mutations and co-occurring variants in cancer biopsies

Our CEO discusses how AI could fit into #precisionmedicine, & why it’s not ready for prime time yet (pg 46): bit.ly/2Is7QAI “We went from AI winning at Jeopardy, to suddenly wanting it to provide information for highly targeted cancer care. That’s too far, too fast."